false
English
Catalog
2021 World Conference on Lung Cancer (Posters)
FP04. Clinical Benefit of First-Line Cemiplimab in ...
FP04. Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Professor Igor Bondarenko from the Dnipropetrovsk Medical Academy in Ukraine shared the results of a subgroup analysis focusing on patients with locally advanced non-small cell lung cancer. The analysis, which was part of the Phase 3 Empower Lung 1 study, found that first-line semi-plumab monotherapy showed superior survival benefits compared to chemotherapy in patients with advanced non-small cell lung cancer without driver mutations and with PD-L1 expression of 50% or more. The safety profile of semi-plumab was comparable to other PD-1 inhibitors. The analysis supports the use of first-line semi-plumab monotherapy in this patient population.
Asset Subtitle
Igor Bondarenko
Meta Tag
Speaker
Igor Bondarenko
Topic
Immunotherapy (Phase II/III Trials)
Keywords
subgroup analysis
semi-plumab monotherapy
survival benefits
PD-L1 expression
patient population
×
Please select your language
1
English
5
普通话
11
Dutch